Chardan Capital Reiterates Buy Rating for SAB Biotherapeutics (NASDAQ:SABS)

Chardan Capital reiterated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a report published on Thursday morning,Benzinga reports. The brokerage currently has a $25.00 target price on the stock.

Other research analysts also recently issued reports about the stock. Craig Hallum began coverage on shares of SAB Biotherapeutics in a research report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a report on Monday, August 12th. Finally, Oppenheimer reissued an “outperform” rating and set a $12.00 price target on shares of SAB Biotherapeutics in a report on Thursday, September 12th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $12.40.

SAB Biotherapeutics Stock Performance

Shares of SABS opened at $3.51 on Thursday. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.07. SAB Biotherapeutics has a one year low of $2.16 and a one year high of $9.72. The business has a fifty day moving average of $2.90 and a 200 day moving average of $3.00.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 87.49%. As a group, sell-side analysts anticipate that SAB Biotherapeutics will post -3.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. First PREMIER Bank bought a new stake in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 19,386 shares of the company’s stock, valued at approximately $60,000. First PREMIER Bank owned 0.21% of SAB Biotherapeutics at the end of the most recent quarter. 7.82% of the stock is owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.